Impact of Timing of Lobectomy on Survival for Clinical Stage IA Lung Squamous Cell Carcinoma

Chest

Volumn 152, Issue 6, 2017, Pages 1239-1250

  Yang, Chi Fu Jeffrey ^a   Wang, Hanghang ^a   Kumar, Arvind ^a   Wang, Xiaofei ^b   Hartwig, Matthew G ^a   D'Amico, Thomas A ^a   Berry, Mark F ^c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

lobectomy; lung cancer; timing of surgery

Indexed keywords

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; EARLY CANCER; FEMALE; HUMAN; LUNG BIOPSY; LUNG LOBECTOMY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SQUAMOUS CELL LUNG CARCINOMA; SURVIVAL TIME; THERAPY DELAY; TIME TO TREATMENT; BIOPSY; CLINICAL TRIAL; EPIDEMIOLOGY; FOLLOW UP; LUNG RESECTION; LUNG TUMOR; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; OPERATION DURATION; PROCEDURES; PROGNOSIS; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TIME FACTOR; TRENDS; UNITED STATES;

AGED; BIOPSY; CARCINOMA, SQUAMOUS CELL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; OPERATIVE TIME; PNEUMONECTOMY; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; TIME-TO-TREATMENT; UNITED STATES;

EID: 85038218454     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1016/j.chest.2017.07.032     Document Type: Article

References (45)

1. Evans, W.K., Prognostic implications of treatment delays in the surgical resection of lung cancer. Thoracic Surg Clin 23:2 (2013), 225–232.
2. SEER. Cancer Statistics Factsheets: Lung and Bronchus Cancer. National Cancer Institute. Bethesda, MD.
3. Aragoneses, F.G., Moreno, N., Leon, P., et al. Influence of delays on survival in the surgical treatment of bronchogenic carcinoma. Lung Cancer 36:1 (2002), 59–63.
4. Quarterman, R.L., McMillan, A., Ratcliffe, M.B., Block, M.I., Effect of preoperative delay on prognosis for patients with early stage non-small cell lung cancer. J Thoracic Cardiovasc Surg, 125(1), 2003 108-113-114.
5. Shin, D.W., Cho, J., Kim, S.Y., et al. Delay to curative surgery greater than 12 weeks is associated with increased mortality in patients with colorectal and breast cancer but not lung or thyroid cancer. Ann Surg Oncol 20:8 (2013), 2468–2476.
6. Gomez, D.R., Liao, K.P., Swisher, S.G., et al. Time to treatment as a quality metric in lung cancer: staging studies, time to treatment, and patient survival. Radiother Oncol 115:2 (2015), 257–263.
7. Kanarek, N.F., Hooker, C.M., Mathieu, L., et al. Survival after community diagnosis of early-stage non-small cell lung cancer. Amer J Med 127:5 (2014), 443–449.
8. Samson, P., Patel, A., Garrett, T., et al. Effects of delayed surgical resection on short-term and long-term outcomes in clinical stage i non-small cell lung cancer. Ann Thoracic Surg 99:6 (2015), 1906–1913.
9. Ettinger, D.S., Wood, D.E., Akerley, W., et al. Non-small cell lung cancer, version 6.2015. J Natl Compr Cancer Netw 13:5 (2015), 515–524.
10. Vansteenkiste, J., Crino, L., Dooms, C., et al. 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. Ann Oncol 25:8 (2014), 1462–1474.
11. Howington, J.A., Blum, M.G., Chang, A.C., Balekian, A.A., Murthy, S.C., Treatment of stage I and II non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 143:5 Suppl (2013), e278S–e313S.
12. Bilimoria, K.Y., Ko, C.Y., Tomlinson, J.S., et al. Wait times for cancer surgery in the United States: trends and predictors of delays. Ann Surg 253:4 (2011), 779–785.
13. Greene, F.L., American Joint Committee on Cancer, American Cancer Society. AJCC Cancer Staging Manual. 6th ed., 2002, Springer, New York.
14. Edge, S.B., American Joint Committee on Cancer. AJCC Cancer Staging Manual. 7th ed., 2010, Springer, New York.
15. Travis, W.D., Brambilla, E., Noguchi, M., et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thoracic Oncol 6:2 (2011), 244–285.
16. Rekhtman, N., Neuroendocrine tumors of the lung: an update. Arch Pathol Lab Med 134:11 (2010), 1628–1638.
17. Bertino, E.M., Confer, P.D., Colonna, J.E., Ross, P., Otterson, G.A., Pulmonary neuroendocrine/carcinoid tumors: a review article. Cancer 115:19 (2009), 4434–4441.
18. Devbhandari, M.P., Bittar, M.N., Quennell, P., et al. Are we achieving the current waiting time targets in lung cancer treatment? Result of a prospective study from a large United kingdom teaching hospital. J Thoracic Oncol 2:7 (2007), 590–592.
19. BTS recommendations to respiratory physicians for organising the care of patients with lung cancer. The Lung Cancer Working Party of the British Thoracic Society Standards of Care Committee. Thorax 53:Suppl 1 (1998), S1–S8.
20. Koike, T., Koike, T., Yoshiya, K., Tsuchida, M., Toyabe, S., Risk factor analysis of locoregional recurrence after sublobar resection in patients with clinical stage IA non-small cell lung cancer. J Thoracic Cardiovasc Surg 146:2 (2013), 372–378.
21. Harrell, F., Regression Modelling Strategies With Applications to Linear Models, Logistic Regression, and Survival Analysis. 2001, Springer Verlag, New York, NY.
22. Adam, M.A., Pura, J., Goffredo, P., et al. Presence and number of lymph node metastases are associated with compromised survival for patients younger than age 45 years with papillary thyroid cancer. J Clin Oncol 33:21 (2015), 2370–2375.
23. Durrleman, S., Simon, R., Flexible regression models with cubic splines. Stat Med 8:5 (1989), 551–561.
24. Desquilbet, L., Mariotti, F., Dose-response analyses using restricted cubic spline functions in public health research. Stat Med 29:9 (2010), 1037–1057.
25. Greenland, S., Dose-response and trend analysis in epidemiology: alternatives to categorical analysis. Epidemiology 6:4 (1995), 356–365.
26. Molinari, N., Daures, J.P., Durand, J.F., Regression splines for threshold selection in survival data analysis. Stat Med 20:2 (2001), 237–247.
27. Saraiya, M., Kottiri, B.J., Leadbetter, S., et al. Total and percent free prostate-specific antigen levels among U.S. men, 2001-2002. Cancer Epidemiol Biomarkers Prev 14:9 (2005), 2178–2182.
28. Travis, W.D., Brambilla, E., Nicholson, A.G., et al. The 2015 World Health Organization Classification of Lung Tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thoracic Oncol 10:9 (2015), 1243–1260.
29. Radzikowska, E., Glaz, P., Roszkowski, K., Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20 561 cases. Ann Oncol 13:7 (2002), 1087–1093.
30. Mohammed, N., Kestin, L.L., Grills, I.S., et al. Rapid disease progression with delay in treatment of non-small-cell lung cancer. Inte J Radiat Oncol Biol Phys 79:2 (2011), 466–472.
31. Everitt, S., Herschtal, A., Callahan, J., et al. High rates of tumor growth and disease progression detected on serial pretreatment fluorodeoxyglucose-positron emission tomography/computed tomography scans in radical radiotherapy candidates with nonsmall cell lung cancer. Cancer 116:21 (2010), 5030–5037.
32. Everitt, S., Plumridge, N., Herschtal, A., et al. The impact of time between staging PET/CT and definitive chemo-radiation on target volumes and survival in patients with non-small cell lung cancer. Radiother Oncol 106:3 (2013), 288–291.
33. Redaniel, M.T., Martin, R.M., Ridd, M.J., Wade, J., Jeffreys, M., Diagnostic intervals and its association with breast, prostate, lung and colorectal cancer survival in England: historical cohort study using the Clinical Practice Research Datalink. PLoS One, 10(5), 2015, e0126608.
34. Buccheri, G., Ferrigno, D., Lung cancer: clinical presentation and specialist referral time. Eur Respir J 24:6 (2004), 898–904.
35. Kanashiki, M., Satoh, H., Ishikawa, H., Yamashita, Y.T., Ohtsuka, M., Sekizawa, K., Time from finding abnormality on mass-screening to final diagnosis of lung cancer. Oncol Rep 10:3 (2003), 649–652.
36. Kashiwabara, K., Koshi, S., Itonaga, K., Nakahara, O., Tanaka, M., Toyonaga, M., Outcome in patients with lung cancer found on lung cancer mass screening roentgenograms, but who did not subsequently consult a doctor. Lung Cancer 40:1 (2003), 67–72.
37. Bozcuk, H., Martin, C., Does treatment delay affect survival in non-small cell lung cancer? A retrospective analysis from a single UK centre. Lung Cancer 34:2 (2001), 243–252.
38. Kashiwabara, K., Koshi, S., Ota, K., Tanaka, M., Toyonaga, M., Outcome in patients with lung cancer found retrospectively to have had evidence of disease on past lung cancer mass screening roentgenograms. Lung Cancer 35:3 (2002), 237–241.
39. Loh, L.C., Chan, L.Y., Tan, R.Y., et al. Effect of time delay on survival in patients with non-small cell lung cancer–a Malaysian study. Asia Pac J Public Health 18:1 (2006), 69–71.
40. Pita-Fernandez, S., Montero-Martinez, C., Pertega-Diaz, S., Verea-Hernando, H., Relationship between delayed diagnosis and the degree of invasion and survival in lung cancer. J Clin Epidemiol 56:9 (2003), 820–825.
41. Salomaa, E.R., Sallinen, S., Hiekkanen, H., Liippo, K., Delays in the diagnosis and treatment of lung cancer. Chest 128:4 (2005), 2282–2288.
42. Annakkaya, A.N., Arbak, P., Balbay, O., Bilgin, C., Erbas, M., Bulut, I., Effect of symptom-to-treatment interval on prognosis in lung cancer. Tumori 93:1 (2007), 61–67.
43. Myrdal, G., Lambe, M., Hillerdal, G., Lamberg, K., Agustsson, T., Stahle, E., Effect of delays on prognosis in patients with non-small cell lung cancer. Thorax 59:1 (2004), 45–49.
44. Neal, R.D., Allgar, V.L., Ali, N., et al. Stage, survival and delays in lung, colorectal, prostate and ovarian cancer: comparison between diagnostic routes. Br J Gen Pract 57:536 (2007), 212–219.
45. Nadpara, P., Madhavan, S.S., Tworek, C., Guideline-concordant timely lung cancer care and prognosis among elderly patients in the United States: A population-based study. Cancer Epidemiol 39:6 (2015), 1136–1144.